UBS O'Connor’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

UBS O'Connor’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,133	Closed	-$120K	–	630
2023 Q3	$120K	Hold	13,133	–	–	﹤0.01%	458
2023 Q2	$277K	Sell	13,133 -937	-7%	-$28.9K	0.01%	469
2023 Q1	$379K	Buy	+14,070	New	+$654K	0.01%	483
2022 Q4	–	Sell	-7,401	Closed	-$1.67M	–	488
2022 Q3	$1.67M	Sell	7,401 -2,742	-27%	-$674K	0.02%	672
2022 Q2	$1.92M	Buy	+10,143	New	+$2.04M	0.02%	667
2019 Q4	–	Sell	-1,713	Closed	-$527K	–	366
2019 Q3	$527K	Buy	+1,713	New	+$556K	0.01%	235
2014 Q4	–	Sell	-56	Closed	-$262K	–	733
2014 Q3	$262K	Buy	+56	New	+$296K	﹤0.01%	394

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's EIGR Position: Q4 2023 in Review

UBS O'Connor sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 13,133 shares — an estimated $120K sold.

UBS O'Connor first reported a position in EIGR in Q3 2014 and held it in 7 quarters. The position peaked at $1.92M in Q2 2022. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

UBS O'Connor reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 13,133 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $120K.
UBS O'Connor first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 7 quarters.
UBS O'Connor's Eiger BioPharmaceuticals, Inc. position peaked at $1.92M in Q2 2022.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.